SQZ Biotechnologies Company (SQZB) Research

SQZ Biotechnologies Company (SQZB) is a clinical-stage biotechnology enterprise focused on developing pioneering cell therapies for individuals battling serious medical conditions, including various cancers, autoimmune disorders, and infectious diseases. At the forefront of its pipeline, SQZ-PBMC-HPV, derived from the SQZ Antigen Presenting Cells platform, is currently in a Phase I clinical trial. This candidate is being assessed as both a monotherapy and in conjunction with immuno-oncology agents for the treatment of advanced or metastatic solid tumors that are HPV16-positive, encompassing cancers such as cervical, head-and-neck, anal, penile, vulvar, and vaginal. Furthermore, SQZ-AAC-HPV is another key candidate progressing through Phase I clinical trials, addressing HPV16-positive advanced or metastatic solid tumors either as a singular treatment or combined with immune-oncology agents. The company is also advancing additional proprietary platforms, specifically SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers. Established in 2013, SQZ Biotechnologies maintains its corporate headquarters in Watertown, Massachusetts.

Open SQZ Biotechnologies Company (SQZB) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.